Stay updated with breaking news from Nasdaq Atha. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Athira Pharma, Inc. (NASDAQ:ATHA – Get Rating) Director James A. Johnson bought 5,000 shares of Athira Pharma stock in a transaction on Wednesday, March 29th. The shares were purchased at an average cost of $2.40 per share, with a total value of $12,000.00. Following the acquisition, the director now directly owns 5,000 shares of the […]
Data highlights potential neuroprotective, neurotrophic and anti-inflammatory effects of enhancing the HGF/MET system...
SG Americas Securities LLC bought a new stake in Athira Pharma, Inc. (NASDAQ:ATHA – Get Rating) during the 2nd quarter, Holdings Channel.com reports. The fund bought 12,504 shares of the company’s stock, valued at approximately $38,000. Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Nisa […]
Additional data showed numerical improvement in activities of daily living (ADCS-ADL23), a protocoled secondary endpoint and a functional measure of...
BOTHELL, Wash., May 19, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on...